Mirum Pharmaceuticals, Inc. Board of Directors

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Ms. Erin Campany

Ms. Erin Campany

Senior Vice President of Human Resources

Andrew McKibben

Andrew McKibben

Vice President of Investor Relations and Finance

Ms. Lara Longpre MBA, MSC

Ms. Lara Longpre MBA, MSC

Chief Development Officer

Mr. Paul K. Ross

Mr. Paul K. Ross

Chief Compliance Officer

Ms. Vinita P. Kumar

Ms. Vinita P. Kumar

Senior vice President of Quality

Dr. Jean-Luc Girardet Ph.D.

Dr. Jean-Luc Girardet Ph.D.

Senior Vice President of Technical Operations

Dr. Pamela Vig Ph.D.

Dr. Pamela Vig Ph.D.

Chief Scientific Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.